Keyphrases
Sublingual Buprenorphine
54%
Opioids
54%
Buprenorphine
53%
Transdermal Buprenorphine
48%
Release Treatment
48%
Maternal Opioid Use
48%
Full Agonist
48%
Postpartum Period
48%
Observational Cohort Study
48%
Hospital Transition
48%
Medications for Opioid Use Disorder
48%
Extended Release
48%
Single Center
11%
Opioid Use Disorder
11%
Clinical Course
10%
Hospitalized Patients
10%
Milligram Morphine Equivalents
10%
Urine Toxicology
6%
Postpartum Patient
6%
High-risk Population
6%
Maintenance Dose
6%
Euphoria
6%
Toxicological Testing
6%
Total Dose
6%
Intoxication
6%
Retrospective Case Series
6%
Last Days
5%
Electronic Medical Records
5%
Retrospective Chart Review
5%
Microdosing
5%
Illicit Opioids
5%
Inclusion Criteria
5%
Initial Dose
5%
Patient-completed
5%
Transition Period
5%
Opioid Withdrawal
5%
Transition Outcomes
5%
Patient Tolerance
5%
In-hospital Outcomes
5%
Standardized Data
5%
Methadone
5%
First Day
5%
One Dose
5%
Transition Strategies
5%
Treatment Protocol
5%
Exclusion Criteria
5%
Improvement Area
5%
Total Daily Dose
5%
Retrospective Observational Study
5%
Precipitated Withdrawal
5%
Pharmacology, Toxicology and Pharmaceutical Science
Diseases
100%
Buprenorphine
97%
Opiate Agonist
48%
Transdermal
48%
Cohort Study
48%
Disease Course
5%
Morphine
5%
Maintenance Dose
5%
Toxic Injury
5%
Toxicology
5%